Atrial-Ventricular Pacing for Tachycardia Discrimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current implantable cardioverter defibrillators (ICDs) face challenges in accurately distinguishing between supraventricular tachycardia (SVT) and ventricular tachycardia (VT) due to similar tachycardia cycle lengths, leading to potential false detections and inappropriate therapy delivery.
Innovation Solution
The implementation of dual chamber burst pacing, where a premature atrial pacing pulse is delivered before dual chamber pacing pulses, allowing for more accurate discrimination between SVT and VT by capturing the atria and blocking retrograde conduction, thereby identifying the chamber of origin for the tachycardia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard tachycardia detection methods are used, then detection speed is maintained, but discrimination accuracy between SVT and VT deteriorates due to similar cycle lengths
Solution Approach 1:
The patent applies preliminary action by delivering a premature atrial pacing pulse before the dual chamber burst pacing sequence. This premature pulse is timed to occur before the tachycardia algorithm would normally terminate, allowing the atria to be captured and retrograde conduction to be blocked. This preliminary action establishes the diagnostic pattern (atrial capture followed by ventricular response) that enables accurate SVT/VT discrimination without extending the overall therapy delivery time, because the premature pulse is integrated into the existing algorithm timeline rather than adding a separate delay.
2Measurement precision
If atrial-ventricular pacing is implemented, then tachycardia discrimination accuracy improves, but device complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the pacing intervention into distinct components: a premature atrial pacing pulse delivered at a specific timing offset, followed by a dual chamber burst pacing sequence. This segmentation allows each component to serve a specific function - the premature pulse captures the atria and blocks retrograde conduction, while the subsequent burst pacing terminates the tachycardia. The segmentation is implemented through separate timing parameters (premature pulse offset, burst pacing parameters) that can be independently programmed, reducing the perceived complexity while maintaining diagnostic accuracy.
3Reliability
If more aggressive pacing therapies are used, then tachycardia termination efficacy improves, but energy consumption increases
Solution Approach 1:
The patent applies feedback by using the response to the premature atrial pacing pulse as a diagnostic indicator. If the premature pulse captures the atria and blocks retrograde conduction (indicating SVT), then less aggressive therapy can be applied. If no such response is observed (indicating VT), then more aggressive pacing or shock therapy is warranted. This feedback mechanism allows the device to adapt the pacing intensity to the actual tachycardia type, avoiding unnecessary high-energy interventions for SVT cases while maintaining high termination efficacy for true VT cases.
Data Source
AI summary
A cardiac medical device and associated method control delivery of dual chamber burst pacing pulses in response to detecting tachycardia. A number of cardiac cycles occurring in a first cardiac chamber are identified subsequent to the dual chamber pacing pulses. The number of sensed intrinsic events occurring in a second cardiac chamber during the first chamber cardiac cycles is determined as a number of second chamber events. The tachycardia episode is classified in response to the number of second chamber events.